Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Vertex_Pharmaceuticals
|
| gptkbp:activities |
potentiates CFTR protein function
|
| gptkbp:approves |
gptkb:legislation
gptkb:United_States January 31, 2012 |
| gptkbp:class |
CFTR modulator
|
| gptkbp:clinical_trial |
Phase 3
approximately 60% |
| gptkbp:contraindication |
hypersensitivity to ivacaftor
|
| gptkbp:developed_by |
gptkb:Vertex_Pharmaceuticals
|
| gptkbp:dosage_form |
oral tablet
|
| gptkbp:formulation |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kalydeco
|
| gptkbp:indication |
G551 D mutation in CFTR gene
|
| gptkbp:ingredients |
gptkb:ivacaftor
|
| gptkbp:invention |
patented
|
| gptkbp:is_atype_of |
R07 A X03
|
| gptkbp:is_used_for |
gptkb:cystic_fibrosis
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:Kalydeco
|
| gptkbp:membership |
gptkb:Vertex_Pharmaceuticals
|
| gptkbp:name |
Essential Medicines
|
| gptkbp:side_effect |
headache
nausea diarrhea rash upper respiratory tract infection |
| gptkbp:social_structure |
C24 H28 N2 O3 S
|
| gptkbp:weight |
396.56 g/mol
|